Please login to the form below
EpiDestiny
This page shows the latest EpiDestiny news and features for those working in and with pharma, biotech and healthcare.
Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug
And as an oral, once-daily drug EpiDestiny’s candidate could be easier to administer - and likely much cheaper - than gene therapies that are in development for SCD and beta-thalassaemia. ... EpiDestiny is hanging on to rights for the drug as a cancer
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
